# Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb

> **NCT04614246** · PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 215 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** BAY1817080
- **DRUG:** Elagolix
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04614246
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-29
- **Primary completion:** 2022-01-17
- **Final completion:** 2022-05-03
- **Target enrollment:** 215 (ACTUAL)
- **Why stopped:** Study terminated by Sponsor
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04614246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04614246, "Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04614246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*